Why is the trial using Dronedarone?

Dronedarone is a rhythm control medicine (antiarrhythmic drug) and has been approved by the U.S. Food and Drug Administration (FDA) in certain patients with atrial fibrillation since 2009. In addition, dronedarone:

  • is well-tolerated
  • is effective in preventing recurrent AFib
  • has been shown to reduce cardiovascular hospitalization
  • is safe
  • post-hoc analyses suggest it performs well in persons with early AFib